EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY

被引：1
|
作者：
Xu, D. [1 ]
Zhang, S. [1 ]
Huang, C. [2 ,3 ]
Huang, C. [2 ,3 ]
Qin, L. [4 ]
Li, X. [5 ]
Chen, M. [6 ]
Liu, X. [7 ]
Liu, Y. [8 ]
Li, Z. [9 ]
Hu, J. [10 ]
Bao, C. [11 ]
Wei, W. [12 ]
Tian, J. [13 ]
Duan, X. [14 ]
Van Vollenhoven, R. [15 ]
Fang, J. [16 ,17 ]
Zeng, X. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Rheumatol, Beijing, Peoples R China
[2] Beijing Hosp, Rheumatol, Beijing, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 2, Rheumatol, Guangzhou, Peoples R China
[4] Huzhou Third Municipal Hosp, Rheumatol, Huzhou, Peoples R China
[5] Anhui Prov Hosp, Rheumatol, Hefei, Anhui, Peoples R China
[6] Xiamen Univ, Affiliated Hosp 1, Rheumatol, Xiamen, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Rheumatol, Taiyuan, Shanxi, Peoples R China
[8] Sichuan Univ, West China Hosp, Rheumatol, Chengdu, Sichuan, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Rheumatol, Bengbu, Peoples R China
[10] Jiangxi Pingxiang Peoples Hosp, Rheumatol, Jianxi, Peoples R China
[11] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Rheumatol, Shanghai, Peoples R China
[12] Tianjin Med Univ, Gen Hosp, Rheumatol, Tianjin, Peoples R China
[13] Cent South Univ, Xiangya Hosp 2, Rheumatol, Xiangya, Peoples R China
[14] Nanchang Univ, Affiliated Hosp 2, Rheumatol, Nanchang, Jiangxi, Peoples R China
[15] Univ Amsterdam, Rheumatol, Med Ctr, Amsterdam, Netherlands
[16] Shanghai Tongi Univ, Rheumatol, Shanghai, Peoples R China
[17] RemeGen Co Ltd, Rheumatol, Yantai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Clinical Trials; Randomized control trial; Sjogren syndrome;
D O I：
10.1136/annrheumdis-2023-eular.1728
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0142
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJOGREN'S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL
    Baer, Alan
    Gottenberg, Jacques-Eric
    St Clair E, William
    Sumida, Takayuki
    Takeuchi, Tsutomu
    Seror, Raphaele
    Foulks, Gary
    Nys, Marleen
    Johnsen, Alyssa
    Wong, Robert
    Ray, Neelanjana
    Bootsma, Hendrika
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 89 - 90
  • [32] Safety and efficacy of paliperidone extendedrelease in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
    Zhang, Hongyan
    Li, Huafang
    Liu, Yanning
    Wu, Cathy
    Wu, Qingqi
    Nuamah, Isaac
    Shi, Jianguo
    Xie, Shiping
    Wang, Gang
    Gopal, Srihari
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 69 - 77
  • [33] DESIGN OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN ANTAGONIST, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME
    Hubbard, J.
    Campbell, K.
    Sivils, K.
    Hoffman, R. W.
    Lo, K. H.
    Leu, J. H.
    Liva, S. G.
    Zuraw, Q.
    Stevens, A. M.
    Berhanu, A.
    Scofield, R. H.
    Seror, R.
    Wallace, D. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 87
  • [34] Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
    D'Urzo, Anthony D.
    Rennard, Stephen I.
    Kerwin, Edward M.
    Mergel, Victor
    Leselbaum, Anne R.
    Caracta, Cynthia F.
    RESPIRATORY RESEARCH, 2014, 15
  • [35] Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
    Anthony D D’Urzo
    Stephen I Rennard
    Edward M Kerwin
    Victor Mergel
    Anne R Leselbaum
    Cynthia F Caracta
    Respiratory Research, 15
  • [36] A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension
    Vannorsdall, Mark D.
    Hariachar, Srinivas
    Hewitt, L. Arthur
    POSTGRADUATE MEDICINE, 2015, 127 (02) : 133 - 143
  • [37] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
  • [38] EFFICACY AND SAFETY OF ROMILKIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK, PROOF OF CONCEPT STUDY
    Allanore, Y.
    Wung, P.
    Soubrane, C.
    Esperet, C.
    Frederic, M.
    Bejuit, R.
    Lahmar, A.
    Khanna, D.
    Denton, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 157 - 158
  • [39] Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
    Allanore, Yannick
    Denton, Christopher
    Khanna, Dinesh
    Soubrane, Christina
    Esperet, Corinne
    Marrache, Frederic
    Bejuit, Raphael
    Lahmar, Amel
    Wung, Peter
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjogren's syndrome
    Bentley, Darren
    Fisher, Benjamin A.
    Barone, Francesca
    Kolb, Fabrice A.
    Attley, Gemma
    RHEUMATOLOGY, 2023, 62 (11) : 3644 - 3653
12345